For information about any of these trials, you may contact the individuals who are listed with each trial or study below, or you may contact us at our general USC MS Comprehensive Care Center number (323-442-6870) or email address (mscare@usc.edu).
Please note that appointments to see our doctors for non-research related care may be made by calling the Weiner Neurology Clinic at 323-442-5710.
Rituximab (RituxanŽ) Treatment In Primary Progressive MS
Status:
CLOSED. Study in follow-up
Sponsors:
Genentech
Type of Study and Brief Description:
A Phase II/III randomized, double-blind, parallel-group placebo controlled multicenter study to determine safety and efficacy of an anti-B cell monoclonal antibody in adults with primary progressive MS. The drug is administered intravenously at various intervals over a 96 week course, with follow-up at 122 weeks.
Background:
Rituxan is a monoclonal antibody that targets and neutralizes B cells, a type of lymphocyte that produces antibodies. There is evidence that B cells, and perhaps some of the antibodies they produce, might contribute to disease in patients with primary progressive MS. This treatment will test whether neutralizing these B cells will be beneficial for this group of patients.
USC Principal Investigator:
Leslie Weiner, MD
Contact:
Pat Guiterrez (323-224-5333 or mstcell@usc.edu).
Additional Information:
You can click here for a document that describes more about this trial.
Back to top
|
